Research Shows Protein's Ability to Prevent HIV Cell Replication - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Research Shows Protein's Ability to Prevent HIV Cell Replication


A family of proteins that promotes virus entry into cells also has the ability to block the release of HIV and other viruses, University of Missouri researchers have found. The study was recently published in the Proceedings of the National Academy of Sciences.

When HIV-1 infects a cell, it replicates and spreads to other cells. T cell immunoglobulin and mucin domain, or TIM-1, has previously been shown to promote entry of some highly pathogenic viruses into host cells. The MU researchers have found that the same protein possesses a unique ability to block the release of HIV-1 and Ebola virus. The TIM proteins prevent viral particles from being released from the infected cell, which may in turn slow the production of the viruses.

The researchers found that as the viral particles attempt to bud from an infected cell, the TIM-family proteins located on the surface of the cell can attach to lipids, known as phosphatidylserine (PS), on the surface of the viral particle. When the TIM-family proteins come in contact with PS, the viral particle becomes attached to the host cell, keeping the particle from being released from the cell. Because TIM-family proteins and PS are present on the surface of the cell and the viral particle, the viral particles get stuck to one another, forming a network of viral particles that accumulate on the surface of the host cell, rather than being released to infect other cells.

By using molecular, biochemical and electron microscopic approaches, the researchers observed the TIM and PS interactions in human cells. Next, the researchers plan to study the biological significance of TIM-family proteins in animals and patients and to determine the fate of the infected cell once it accumulates a buildup of viral particles.

Source: University of Missouri

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here